Welcome to
Epitope.us


Epitope Receives Clearance and First Order for Cotinine Testing in Japan

    BEAVERTON, Ore., Feb. 19 /PRNewswire/ -- Epitope, Inc. (Nasdaq: EPTO)
today announced that its OraSure oral specimen collection device has been
approved for cotinine testing of life insurance applicants in Japan.  Epitope
also announced that it had received its first order for OraSure devices to be
used in Japan for cotinine testing.  Cotinine is a nicotine derivative that
indicates whether the subject is a smoker.
    The Finance Ministry of Japan announced last week that it would permit
life insurance companies to charge lower premiums for nonsmokers and approved
the use of the OraSure device to test applicants for cotinine.  The Finance
Ministry also stated that it had approved applications by two life insurance
companies to reduce premiums for new nonsmoker policies by as much as
30 percent.
    "We are pleased that OraSure has been approved for cotinine testing in the
important Japanese life insurance market," said John W. Morgan, president and
chief executive officer of Epitope.  "Less than 10 percent of new life
insurance applicants in Japan currently receive any type of testing.  We
expect that the advent of nonsmoker premiums will dramatically increase the
extent of testing in Japan."
    The initial order for 20,000 OraSure devices was received through
Epitope's Tokyo-based joint venture partner, Epitope KK.  The OraSure devices
will be used for testing applicants beginning March 2, 1998.
    While nonsmoker policies have been available in the United States since
the mid-1960s, in Japan the introduction of such policies has been delayed on
the grounds that no link had been established between smoking and death rates.
The recent deregulation of the insurance market in Japan has led insurance
companies to develop new premium schedules that reflect applicant risks,
including smoking.
    In 1996, the life insurance market in Japan was served by 44 companies
which sold approximately 35 million policies.  More than one-third of these
policies were new ordinary life policies.  Applicants for ordinary life
policies are the most likely to be tested for smoking and other risk factors.
    Epitope, Inc., is an Oregon based corporation that develops and markets
medical diagnostic products.  Its principal products, including the OraSure
oral specimen collection device, focus on the use of oral fluid to detect HIV
infection and other conditions, and are marketed primarily in the life
insurance and public health sectors.

Source: EPITOPE Inc.


Content of this page is copyright and reprinted here for educational and historical information.
Copyright 2004 - 2018 - Ekim Notnud - All rights Reserved
This site is an unofficial historical site and not affiliated with Epitope, Inc.


  Click for Heirloom Tomato Seed Selection Victory Seed Company Save Seeds - Victory Horticultural Library